Troglitazone

曲格列酮

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameTroglitazone
Drug Alias Nametroglitazonum曲格他唑troglitazonetroglitazonaRezulin +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsGlucose IntoleranceDiabetes Mellitus, Type 2Diabetes Mellitus +[5] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1997/01/29
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteParke-Davis GmbhParke Davis Pharmaceutical Research Div Warner Lambert Co +[5] 
Active IndicationsN/A
Inactive IndicationsGlucose IntoleranceDiabetes Mellitus, Type 2Diabetes Mellitus +[5] 

Other Information

ATC CodeA10BG01
Related LinksWikipediaDrugBankKEGG